全外显子HBV DNA整合独立于肝内HBV储存库
该研究分析84例HBeAg阴性慢性乙型肝炎患者肝组织,发现全外显子HBV DNA整合在高、中、低病毒载量患者中均存在,频率0.5-157整合/1000肝细胞,且整合位于致癌相关基因并改变肝细胞转录组,HBsAg>5000 IU/mL可预测外显子整合。
要点
- HBeAg阴性CHB患者中全外显子HBV DNA整合普遍存在,不依赖肝内HBV储存库水平。
- HBsAg>5000 IU/mL可预测外显子整合,整合频率范围0.5-157整合/1000肝细胞。
- 整合位于致癌、脂质/药物代谢及抗病毒/炎症反应相关基因,并改变转录组。
核心结论
- HBV DNA整合发生于所有HBeAg阴性CHB患者,包括肝内HBV储存库有限者,整合位于致癌相关基因并改变肝细胞转录组。
研究设计与样本
- 分析84例HBeAg阴性CHB患者肝组织,血清HBV DNA低(n=12)、中(n=25)、高(n=47)。
- 采用定量PCR检测cccDNA和pgRNA,Illumina进行全外显子和转录组测序,微滴数字PCR评估HBV DNA整合负荷。
主要发现
- 低与中等血清HBV DNA患者肝内cccDNA和pgRNA相当,显著低于高HBV DNA患者;乙型肝炎核心相关抗原与肝内HBV储存库强相关,反映cccDNA数量。
- 全外显子整合在高、中、低病毒载量患者中分别检出55.6%、14.3%和25%,频率范围0.5-157整合/1000肝细胞。
- HBsAg>5000 IU/mL预测外显子整合,整合位于致癌、脂质/药物代谢及抗病毒/炎症反应相关基因。
- 包括原癌基因hRAS在内的特定基因转录水平在HBV DNA整合患者中更高,提示低至中等病毒载量患者存在潜在致癌风险。
关键数值与推荐
- 全外显子整合检出率:高病毒载量55.6%,中等14.3%,低25%。
- 整合频率范围0.5-157整合/1000肝细胞。
- HBsAg>5000 IU/mL预测外显子整合。
临床怎么用
- 对HBeAg阴性CHB患者应关注HBV DNA整合,即使病毒载量低或肝内HBV储存库有限。
- HBsAg>5000 IU/mL可能提示外显子整合风险,需加强监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The involvement of HBV DNA integration in promoting hepatocarcinogenesis and the extent to which the intrahepatic HBV reservoir modulates liver disease progression remains poorly understood. We examined the intrahepatic HBV reservoir, the occurrence of HBV DNA integration and its impact on the hepatocyte transcriptome in hepatitis B 'e' antigen (HBeAg)-negative chronic hepatitis B (CHB). DESIGN: Liver tissue from 84 HBeAg-negative patients with CHB with low (n=12), moderate (n=25) and high (n=47) serum HBV DNA was analysed. Covalently closed circular DNA (cccDNA), pregenomic RNA (pgRNA) were evaluated by quantitative PCR, whole exome and transcriptome sequencing was performed by Illumina, and the burden of HBV DNA integrations was evaluated by digital droplet PCR. RESULTS: Patients with low and moderate serum HBV DNA displayed comparable intrahepatic cccDNA and pgRNA, significantly lower than in patients with high HBV DNA, while hepatitis B core-related antigen correlated strongly with the intrahepatic HBV reservoir, reflecting cccDNA quantity. Whole exome integration was detected in a significant number of patients (55.6%, 14.3% and 25% in high, moderate and low viraemic patients, respectively), at a frequency ranging from 0.5 to 157 integrations/1000 hepatocytes. Hepatitis B surface antigen >5000 IU/mL predicted integration within the exome and these integrations localised in genes involved in hepatocarcinogenesis, regulation of lipid/drug metabolism and antiviral/inflammatory responses. Transcript levels of specific genes, including the proto-oncogene hRAS, were higher in patients with HBV DNA integration, supporting an underlying oncogenic risk in patients with low-level to moderate-level viraemia. CONCLUSIONS: HBV DNA integration occurs across all HBeAg-negative patients with CHB, including those with a limited HBV reservoir; localising in genes involved in carcinogenesis and altering the hepatocyte transcriptome.
引用
- Svicher V, Salpini R, Piermatteo L, et al. Whole exome HBV DNA integration is independent of the intrahepatic HBV reservoir in HBeAg-negative chronic hepatitis B. Gut. 2020. PMID: 33402415. doi:10.1136/gutjnl-2020-323300
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。